UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and clinical applications with no new human data or systematic synthesis.
PubMed 31236688 · doi:10.1007/164_2019_241
What was done
This narrative review summarizes experimental and clinical data regarding bile acid physiology, mechanisms of cell injury and adaptive responses in cholestasis, and the therapeutic applications of hydrophilic bile acids including ursodeoxycholic acid (UDCA), tauroursodeoxycholic acid (TUDCA), and norursodeoxycholic acid (NorUDCA).
What was found
The abstract provides a qualitative overview of bile acid mechanisms and clinical applications. No specific numerical data, effect sizes, or trial results are reported.
Why it matters
It outlines the physiological and mechanistic rationale for using specific hydrophilic bile acids to treat cholestatic liver diseases and protect biliary epithelia.
Limits
The abstract describes a narrative review without systematic search methodology, meta-analysis, or primary clinical data, and reports no quantitative outcome measures or sample sizes.
Cited by
- supports TUDCA thins bile, promotes bile flow, and acts as an antibacterial disinfectant in the small intestine.